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Abstract 
Multimorbidity is a major challenge for patients and healthcare providers. The limited evidence of the effective-
ness of interventions for people with multimorbidity means that there is a need for much more research and trials 
of potential interventions. Here we present a consensus view from a group of international researchers working 
to improve care for people with multimorbidity to guide future studies of interventions. We suggest that there is 
a need for careful consideration of whom to include, how to target interventions that address specific problems 
and that do not add to treatment burden, and selecting outcomes that matter both to patients and the healthcare 
system. Innovative design of these interventions will be necessary as many will be introduced in service settings 
and it will be important to ensure methodological rigour, relevance to service delivery, and generalizability 
across healthcare systems.
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Introduction
Multimorbidity, sometimes referred to as multiple 
chronic conditions, is defined as the co-existence of two 
or more chronic conditions in the same individual and 
includes both physical and mental health conditions [1]. 
Multimorbidity carries a substantial burden, not only for 
individuals, as it is associated with lower quality of life 
and lower levels of functioning, but also for healthcare 
delivery in terms of high utilization rates and complex 
care needs [2]. Prevalence increases with age, but in 
absolute terms there are more middle-aged people liv-
ing with multimorbidity [3,4]. Multimorbidity is also 
strongly associated with socioeconomic deprivation 
– with those in the most deprived groups developing 
multimorbidity approximately 10 years earlier than 
those in the most affluent groups [3]. Inter-related issues 
that add to the challenges of multimorbidity include: 
polypharmacy and adverse drug events, multifactorial 
symptom burden, treatment burden (as conditions and 
related treatments escalate), and the added complexity 
of combined physical and mental illness.
Despite the high prevalence of multimorbidity, 
evidence-based medicine and clinical practice guide-
lines are largely informed by trials focusing on single 
conditions and excluding patients with multimorbid-
ity [5]. There is limited evidence of effectiveness of 
interventions, and a recent Cochrane review identi-
fied only 10 trials in this area [6]. Thus, there is a clear 
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need to focus on intervention development and evalu-
ation to address the challenges of multimorbidity [7]. 
Our experience as an international group actively 
engaged in multimorbidity research suggests that, 
although the Medical Research Council Framework 
for the Design and Evaluation of Complex Interven-
tions to improve health outcomes [8] is both relevant 
and useful to guide research on interventions for mul-
timorbidity, there are specific methodological issues 
relating to multimorbidity that need to be considered 
and addressed. 
This paper aims to guide researchers developing and 
evaluating interventions for patients with multimorbid-
ity, and is based on a forum held at the North American 
Primary Care Research Group meeting in 2012. While 
the methodological issues are outlined in sequence, they 
need to be considered in an iterative fashion as each issue 
informs previous and subsequent decision-making, as 
illustrated by Figure 1.
Clarify specific research question
Given the diversity of the population with multimorbid-
ity, it is important to formulate a clear research question. 
Questions must focus on generalizable processes, while 
at the same time retaining the ability to assess the effec-
tiveness of an intervention in specific subpopulations. 
The traditional Population, Intervention, Comparison, 
Outcome (PICO) format may require revisions. It may 
be best to initially focus on designing interventions 
that address specific outcomes, and subsequently iden-
tify subpopulations that are at risk for the outcome and 
are suited for the proposed intervention. For example, 
“How effective are pharmacist-led medicines reviews 
at reducing potentially inappropriate prescribing in 
patients with multimorbidity and polypharmacy?” 
Working closely with patient groups and policy makers 
to identify relevant outcomes may also help guide the 
development of appropriate questions.
Define participants
The key issue when considering participant selection is 
to ensure external validity, while at the same time dem-
onstrating effectiveness – often a challenge within this 
heterogeneous group [9]. There has been much discus-
sion on the challenges of defining multimorbidity, which 
can range from disease counts, with or without restricted 
condition lists, to more sophisticated weighted scores 
incorporating symptom severity [10]. The most inclu-
sive and simplest approach is to consider all individuals 
with two or more chronic conditions; though it is also 
necessary to clarify what is meant by a “chronic con-
dition” [10]. However, this approach will include those 
who may not be in need of intervention, and others who 
may not be amenable to particular approaches. It may, 
therefore, be preferable to target people at higher risk of 
adverse outcomes who will be most likely to benefit from 
interventions. People with four or more conditions have 
poorer outcomes and escalating health-service utilization 
[11,12]; so selecting participants with higher numbers 
of conditions may be more appropriate. Depending on 
the outcomes of interest, other selection criteria might 
include condition severity, symptom burden, poly-
pharmacy, specific age groups, and high health-service 
utilization, including recent hospitalization. 
Some interventions may lend themselves to popu-
lations having concordant conditions with shared risk 
factors. For example, an intervention to promote physi-
cal activity could benefit individuals with coexisting 
obesity, depression, and vascular risk factors. Interven-
tions targeting patients with combined physical and 
mental health problems must also account for complex 
social factors, as this combination is most commonly 
associated with socioeconomic deprivation. Examples of 
other vulnerable subpopulations include migrants, those 
with cognitive impairment or literacy problems, and 
those with more complex and symptomatic conditions. 
Target populations and inclusion and exclusion cri-
teria must be carefully described to address the issue of 
generalizability and external validity. We also recom-
mend paying particular attention to contextual factors 
that may affect generalizability by including a complete 
list of diagnoses of participants (with associated severity) 
as well as other factors, such as social support, cultural 
background and socioeconomic position.
Developing the intervention: theoretical 
underpinning and potential components 
Most interventions addressing multimorbidity are likely 
to be multifaceted and it is very important to have a 
conceptual understanding of how different intervention 
components are likely to affect outcomes. Determining 
causal pathways will necessarily be an iterative process, 
which can be aided by logic models and other diagram-
matic representations. In this regard, interventions 
targeted at people with multimorbidity are no different 
to those targeted at other groups, and in a multifac-
eted intervention, there may be more than one theory 
or evidence base to draw on. For example, for inter-
ventions directed at individuals with multimorbidity, 
identifying specific techniques that support behavioural 
changes are particularly important [13]. However, for 
interventions addressing polypharmacy, the theory and 
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help people “live well with multimorbidity” has involved 
patients, healthcare professionals, voluntary organiza-
tions, and academics in the development, refinement, and 
optimization of the intervention [17]. 
Consider study design
The most likely study designs in this context are prag-
matic randomized trials. For interventions targeted at 
practices or care systems, cluster randomization may 
be ideal; however, this may require prohibitively large 
sample sizes. Study designs depend on the outcomes of 
interest, whether the outcome is measured at the level of 
the patient or the practice, and the expected effect size 
of the intervention. Interventions with large effect sizes 
may be feasible in terms of sample size, but important 
population-level interventions, such as emergency admis-
sions, may have relatively small effect sizes [19]. The use 
of intermediate process outcomes, known to be linked to 
outcomes, such as admissions and Emergency Department 
visits, may help get around the need for large sample sizes. 
Individual randomization is feasible for some of the more 
patient-oriented interventions, such as self- management 
support programmes or specifically designed occupa-
tional health or physiotherapy interventions that also lend 
themselves to the use of waiting-list controls. 
More imaginative approaches to study design include 
stepped wedge designs that have the advantage of allowing 
evidence underpinning medicines management need to 
be considered. 
The recent Cochrane review of interventions to improve 
outcomes for patients with multimorbidity adapted the 
Cochrane Effective Practice and Organisation of Care 
(EPOC) Group Taxonomy for interventions [14], which 
can also be used to identify components of multifaceted 
interventions, and facilitates consideration of the theoreti-
cal underpinning and evidence base for each component. 
The taxonomy is outlined in Table 1 with examples of 
potential interventions for patients with multimorbidity. 
Participatory intervention development with explicit 
involvement of patients, families and carers, and clini-
cal care providers or policy makers, consistent with the 
strong movement towards patient-centred outcomes 
research [15], may also be appropriate. As with identify-
ing a research question, there is a need to balance tailoring 
interventions to the needs of individuals who have multi-
morbidity with delivering standardized interventions that 
are easier to coordinate, monitor, and evaluate. Interven-
tion development may also be informed by the growing 
qualitative literature on multimorbidity that considers the 
patient and provider perspectives [16–18]. The combina-
tion of theory and evidence with practical experience, 
gained through participatory research, is likely to be 
powerful in developing interventions that operate at 
different levels. For example, recent research in areas of 
high deprivation in Scotland has taken a “co-production” 
approach: a complex primary care-based intervention to 
Table 1 Taxonomy of interventions.
Intervention type  Example and how it might work
Professional interventions  Intervention designed to change the behaviour of clinicians; for example, by altering professionals awareness 
of multimorbidity or providing training or education designed to equip clinicians with specific skills in 
managing multimorbidity, including supporting patients, to prioritize their concerns or enhance shared 
decision-making
Financial interventions  Financial incentives to providers; for example, incentivizing health-service delivery and providing resources 
to extend consultation length for patients with multimorbidity
Organizational interventions  Organizational changes; for example, any changes to care delivery such as case management or integrating 
the work of different healthcare workers, such as a pharmacists and general practitioners. Such interventions 
may work by re-orienting care delivery to match the specific needs of patients with multimorbidity, 
including care coordination, medicines management, or specific physiotherapy or occupational therapy 
interventions to address needs relating to physical and social functioning. These may also include 
technological or information technology interventions designed to enhance care coordination and 
communication
Patient-oriented interventions This would include any intervention directed primarily at patients; for example, to help make changes to 
improve well-being, or focus on areas of lifestyle important to them (such as losing weight or increasing 
physical activity). Patient education or support for self-management, which might work by improving self-
management, thus enabling patients to manage their conditions more effectively and to seek health care 
more appropriately. Interventions to improve shared decision-making and prioritization of problems
Regulatory interventions  Changes to local or national regulations designed to alter care delivery; for example, inclusion of annual 
medication reviews in contracts with care providers
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incorporation of service delivery in a phased way and which 
can also increase power. This design can be adopted in the 
context where phased service development is planned in 
an area and where it would be unacceptable to randomize 
participants to waiting lists or usual care within the same 
centre. This may be particularly useful for patients with 
more complex multimorbidity when randomization is not 
feasible or practitioners do not feel comfortable randomiz-
ing such patients to usual care or waiting-list controls. For 
example, a study in Australia using Mental Health Expe-
rience Co-Design (MH ECO) methodology (see http://
mheco.org.au/) involves eight community health centres 
that are being brought into the intervention in random 
order at intervals over 4 years. This design is useful when 
the number of clusters is very low and the research team 
has no control over their number. For best results, the 
stepped wedge design requires that interventions are likely 
to result in rapid and large changes in outcomes. However, 
this design is no panacea and will usually require more 
outcome measurements and more time than cluster ran-
domized trials [20]. Mixed method designs incorporating 
both quantitative and qualitative methods are likely to be 
of particular importance given the complexity of popula-
tions and interventions. Quasi-experimental designs, such 
as controlled before and after studies, may also be consid-
ered for pragmatic reasons as they may be more acceptable 
for patients with multimorbidity in service-delivery set-
tings. The key issue when choosing any design is that it is 
robust enough to contribute to the existing evidence and 
be incorporated into systematic reviews [21]. 
Selecting outcomes
The key aspect of outcome selection is matching out-
comes to the proposed mechanisms of action for each 
component of the intervention. We have found it helpful 
to group outcomes into clinical outcomes, patient out-
comes or patient-reported outcome measures (PROMs), 
and healthcare system outcomes. These are described 
in more detail here with examples given in Table 2. 
Clinical outcomes are challenging in a population with 
a variety of conditions, and innovative approaches are 
required to assess physical health outcomes. A good 
example of a potentially useful approach for broadly 
designed interventions has been developed by Reeves 
et al., who combined multiple indicators of clinical qual-
ity across a range of 23 acute and chronic conditions, 
and measured the proportion of disease targets, which 
were met for each condition [22]. 
Intermediate outcomes (sometimes thought of as 
mediating variables, such as self-efficacy or health 
behaviours) that are associated with “hard outcomes”, 
such as hospital admission or mortality, are particularly 
useful, as many “hard outcomes” may be difficult to 
assess directly due to long follow-up times or difficulty 
with large-scale data collection. These associations can 
be illustrated in a logic model to demonstrate the rela-
tionship between more proximal and distal outcomes. 
Disease-specific outcomes may not be appropriate 
as primary outcomes in patients with multimorbidity 
because (i) there will be multiple combinations of indi-
vidual conditions and (ii) they may have less to gain from 
ideal control of each individual disease. The guidance for 
individual diseases may not be applicable to these com-
plex patients because the underlying research excluded 
individuals with comorbidities, and maximizing treatment 
may not reflect their own priorities, especially if it leads 
to polypharmacy and extensive investigation. A conse-
quence of maximizing care for individual diseases could 
be excessive treatment burden. A validated treatment 
burden measure is currently being developed which may 
be particularly useful for the population with multimor-
bidity [23]. Other outcomes might include avoidance of 
unnecessary tests and minimizing medication side effects. 
In the setting of multimorbidity, an intervention that aims 
to be responsive to people’s own priorities and reduces 
over-treatment may conceivably lead to reduced perfor-
mance on conventional measures of disease control (e.g. 
tight control of blood pressure) while still successfully 
achieving its aims. However, the focus on the patients’ 
agenda must be balanced by clinical knowledge and, in 
some cases, a focus on individual condition management 
may remain important. For example, there is sufficient 
evidence to support optimal medical management of con-
gestive cardiac failure, both in reducing mortality and in 
reducing admissions and troublesome physical symptoms, 
such as breathlessness. However, an agenda entirely driven 
by patient priorities may not recognize this, highlighting 
the importance of shared decision-making and clinical 
expertise. Generic outcomes that focus on quality of life 
and functional capacity should also improve with optimal 
medical management, where this is evidence-based and 
appropriate. 
Finally, health systems will be particularly interested 
in identifying cost-effective processes of care that mini-
mize unintended consequences for the population with 
multimorbidity. The incorporation of health-related 
quality-of-life outcomes will enable economic analyses 
with a broader perspective in terms of additional qual-
ity-adjusted life years gained. 
Analysis and interpretation of results
Analysis of results will need to follow recom-
mended guidelines based on trial design (see www.
equator-network.org). Careful process evaluations 
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Table 2 Potential outcomes in multimorbidity research.
Domain  Example of measure  Comment
Clinical
Disease-specific measures   Only relevant for comorbidity studies where interventions 
directed at all included comorbid conditions 
Clinical quality indicators   Promising approach assessing proportions of indicators met 
across conditions
Risk factors  BP, lipids  May be more relevant for certain condition combinations
Body weight  Weight/BMI, waist–hip ratios  More relevant across certain conditions
Frailty/physical fitness   The measures frequently require clinical assessment, physical 
testing or at a minimum patient self-report
Patient-reported outcome measures
Psychological  Self-efficacy  Need clear link with theoretical underpinning of intervention
 HRQoL
 Well-being
 Measures of anxiety and depression
Behaviour and daily 
functioning
 Physical functioning
 Activities of daily living
 Self-management behaviours
 Health behaviours
 Number of days out of role  
 Smoking  May be more relevant in longer-term studies when trying to 
prevent further decline
Social  Social inclusion and participation  
 Social support  
 Patient engagement and 
empowerment
 
Treatment burden   
Shared decision-making   
Goal setting   
Satisfaction with care 
provision
  
Healthcare system
Health-service utilization  Provider visits  Can be hard to determine what is appropriate change, 
depending on baseline provision
 Admissions  Determine which admissions are sensitive to changes in 
ambulatory-care delivery
Process of care  Risk-factor recording  May be more relevant for specific condition combinations
 Annual reviews  Depends on goals of care
Accessibility of services   
Safety indicators  Adverse drug events  Challenging to measure due to inconsistent documentation and 
need for expert chart review
Healthcare provider measures
Satisfaction with care 
delivery
  
“Burn-out”   
Confidence and competence 
in deliver care
Self-efficacy  Confidence in ability to deliver care 
 Knowledge  May be relevant for medicines management
 Skill  Ability to deliver behavioural change based interventions
Cost outcomes
Costs of care   
Indirect costs   
Other outcomes
Carer burden   Including outcomes for children of patients with multimorbidity
Alignment of treatment 
goals between patients 
and providers
  
BMI, body mass index; BP, blood pressure; HRQoL, health-related quality of life.
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incorporating both quantitative methods (e.g. how 
many people received the intervention as intended) and 
qualitative methods (e.g. how the intervention is imple-
mented, what worked, and what did not work) will be 
needed to document how interventions are operational-
ized and to allow replication or potential adaptations for 
other settings [24]. This should include description of 
the context, i.e. the patient population, the community, 
and the healthcare setting, as a means of understand-
ing whether and how an intervention will generalize to 
other settings. A formal process evaluation should also 
assess treatment burden as a result of participation in the 
intervention itself. Many interventions will be designed 
to work at two levels: (i) changes in healthcare organiza-
tion and/or clinician behaviour, which are intended to 
lead to (ii) changes in patient behaviour. It is important 
to examine both levels in a process evaluation. An inter-
vention may fail because it is not fully implemented by 
the clinicians, or because it is fully implemented, but is 
not effective at changing patient behaviour.
Disease type and severity may also influence out-
comes; therefore, accurate measurement of morbidity 
(including self-reported morbidity burden or symptom 
severity) becomes important in interpreting results. 
With multimorbidity, it is important to try to identify 
subgroups who respond in particular ways, and to exam-
ine the likely impact of the intervention on reducing 
inequalities in health, though such analyses may require 
boosting of sample sizes. Investigators undertaking clus-
ter randomized trials should also publish the observed 
intra-cluster correlation coefficients for key outcomes, 
to inform the sample size calculations for future studies. 
Conclusion
Multimorbidity is increasingly important and we need 
cost-effective interventions to improve outcomes in this 
group of patients in all healthcare systems. People with 
multimorbidity are, by definition, a heterogeneous group, 
and different interventions may be required for different 
subgroups, depending on condition severity, condition 
combinations, social circumstances, or age. Multimorbidity 
intervention research raises substantial ethical issues that 
need to be tackled – the obvious one being, “who decides 
what is a good outcome?” Involvement of patients, fam-
ily members, clinicians, and policy makers in developing 
research questions and interventions would help address 
these issues. This reinforces the importance of good quali-
tative research, both to develop and evaluate interventions 
and to contribute to the debate. There is a need to clearly 
report participant characteristics, intervention components 
and delivery, and results in a way that enables comparison 
across trials, and to ensure that future trials can be incor-
porated into updated systematic reviews. Multimorbidity 
research will also illustrate, and perhaps magnify, tensions 
present in patient-centred care delivery, which involve 
prioritization and shared decision-making and making 
choices in the face of multiple potential outcomes.
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